{"title": "Long-COVID: Impfung und fr\u00fche antivirale Therapie senken das Risiko", "author": "Kr\u00fcger; Stefan", "url": "https://dx.doi.org/10.1159/000530014", "hostname": "doi.org", "description": "Abstract. Long COVID is a complex condition affecting quality of life, with limited therapeutic options. We investigated the occurrence of long COVID in subjects receiving early therapy with monoclonal antibodies (mAbs) or antivirals to reduce the risk of COVID-19 progression. In this retrospective study we enrolled 737 adult patients (aged 65.16 \u00b1 13.46; 361F), who experienced COVID-19 between January 2021 and March 2022. Antiviral or mAbs were administered to symptomatic patients who did not require oxygen therapy or hospital admission for SARS-CoV-2 infection, and who were at high risk of progression to severe disease, as identified by age > 65 years or the presence of comorbidities. Long COVID, defined as newly or persistent long-term symptoms 4 weeks after the onset of the acute illness, was reported in 204 cases (28%). Age (OR 1.03; p < 0.001), gender (OR 1.88; p < 0.001) and at least three comorbidities (OR 3.49; p = 0.049) were directly associated with long COVID; conversely, vaccination (OR 0.59; p = 0.005) and mAbs/antivirals (OR 0.44; p = 0.002) were independently associated with a reduced risk of long COVID. At a propensity-score-matched analysis, the mAbs/antivirals group had a significantly lower occurrence of long COVID in comparison with untreated controls (11% vs. 34%; p= 0.001). In conclusion, mAbs and antivirals administered against the progression of COVID-19 were associated with a reduced risk of long COVID.", "sitename": "Karger Publishers", "date": "2023-04-03", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Abstract\nLong COVID is a complex condition affecting quality of life, with limited therapeutic options. We investigated the occurrence of long COVID in subjects receiving early therapy with monoclonal antibodies (mAbs) or antivirals to reduce the risk of COVID-19 progression. In this retrospective study we enrolled 737 adult patients (aged 65.16 \u00b1 13.46; 361F), who experienced COVID-19 between January 2021 and March 2022. Antiviral or mAbs were administered to symptomatic patients who did not require oxygen therapy or hospital admission for SARS-CoV-2 infection, and who were at high risk of progression to severe disease, as identified by age > 65 years or the presence of comorbidities. Long COVID, defined as newly or persistent long-term symptoms 4 weeks after the onset of the acute illness, was reported in 204 cases (28%). Age (OR 1.03; p < 0.001), gender (OR 1.88; p < 0.001) and at least three comorbidities (OR 3.49; p = 0.049) were directly associated with long COVID; conversely, vaccination (OR 0.59; p = 0.005) and mAbs/antivirals (OR 0.44; p = 0.002) were independently associated with a reduced risk of long COVID. At a propensity-score-matched analysis, the mAbs/antivirals group had a significantly lower occurrence of long COVID in comparison with untreated controls (11% vs. 34%; p= 0.001). In conclusion, mAbs and antivirals administered against the progression of COVID-19 were associated with a reduced risk of long COVID.\nAbstract aus Cimellaro A, Addesi D, Cavallo M, On Behalf Of The CATAnzaro LOng Covid Cataloco Study Group: Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control Study. Biomedicines. 2022 Dec 5;10(12):3135.\nTransfer in die Praxis von Prof. Dr. Stefan Kr\u00fcger (D\u00fcsseldorf)\nHintergrund\nIm Rahmen der COVID-19-Pandemie ist es zu vielen SARS-CoV-2 (severe acute respiratory syndrome coronoavirus 2)-Infektionen gekommen. Ein wesentlicher Teil der Patienten mit einer akuten SARS-CoV-2-Infektion entwickelt ein Long-COVID-Syndrom. Dies ist definiert als das Auftreten oder Persistieren von Symptomen oder langfristigen Komplikationen nach Ablauf von 4 Wochen seit Beginn der akuten Infektion.\nDie Fragestellung der aktuellen italienischen Studie von Antonio Cimellaro und Kollegen war daher, ob eine fr\u00fche Therapie mit monoklonalen Antik\u00f6rpern oder antiviraler Medikation gegen SARS-CoV-2 die Wahrscheinlichkeit f\u00fcr das Auftreten eines Long-COVID-Syndroms reduzieren kann.\nErgebnisse der Studie\nIn der monozentrischen retrospektiven Studie wurden 737 erwachsene Patienten mit einer akuten SARS-CoV-2-Infektion zwischen Januar 2021 und M\u00e4rz 2022 eingeschlossen. Bei 135 symptomatischen Patienten (18%) mit einem hohen Risiko f\u00fcr die Entwicklung eines schweren Verlaufs (Alter >65 Jahre, Komorbidit\u00e4ten) ohne aktuelle Notwendigkeit f\u00fcr eine Hospitalisation oder Sauerstofftherapie wurde eine Therapie mit antiviralen Medikamenten oder monoklonalen Antik\u00f6rpern durchgef\u00fchrt. Im weiteren Verlauf kam es bei 204 Patienten (28%) zur Entwicklung eines Long-COVID-Syndroms. Die Wahrscheinlichkeit f\u00fcr ein Long-COVID-Syndrom war signifikant h\u00f6her bei steigendem Alter, bei Frauen und bei Vorliegen von mindestens 3 Komorbidit\u00e4ten. Durch eine vorhergehende COVID-Impfung (OR 0,59) und durch eine antivirale Therapie (OR 0,44) konnte das Risiko f\u00fcr ein Long-COVID-Syndrom im Vergleich zu ungeimpften Personen bzw. Patienten ohne antivirale Therapie signifikant reduziert werden. Mussten die Patienten hospitalisiert werden, so war die Wahrscheinlichkeit f\u00fcr ein Long-COVID-Syndrom deutlich erh\u00f6ht (9% vs. 2%).\nFazit f\u00fcr die Praxis\nWas bedeutet das f\u00fcr die Praxis? Die Ma\u00dfnahmen, die vor der Entwicklung eines Long-COVID-Syndroms sch\u00fctzen, sind die Impfung gegen SARS-CoV-2 und eine fr\u00fche antivirale Therapie. Die hohe Bedeutung der Impfung wurde in den letzten Jahren breit diskutiert. Sie sch\u00fctzt nachgewiesen vor einem schweren Verlauf der Infektion, vor Tod und vor Hospitalisierung und wie wir sehen auch gegen die Entwicklung eines Long-COVID-Syndroms. Die Medikation mit antiviralen Medikamenten oder monoklonalen Antik\u00f6rpern sch\u00fctzt ebenfalls vor einem schweren Verlauf, Tod, Hospitalisierung und ebenso gegen die Entwicklung eines Long-COVID-Syndroms. Daher sollten wir auch in Zukunft weiterhin f\u00fcr eine breite Akzeptanz der SARS-CoV-2-Impfung werben. Im Falle einer akuten Erkrankung sollte insbesondere bei Patienten mit einem erh\u00f6hten Risiko f\u00fcr einen schweren Verlauf eine antivirale Therapie unbedingt in Erw\u00e4gung gezogen werden.\nDisclosure Statement\nEs bestehen keine Interessenskonflikte in Bezug auf den vorliegenden Wissenstransfer.", "language": null, "image": "https://karger.silverchair-cdn.com/karger/content_public/journal/kkp/issue/11/2/7/m_282923_cover.png?Expires=1761159389&Signature=wsTNdUR0UwrH6im3VPoE5AbLKROZh1tRL2mDI2Jw93BDYtQIs~TbAHIIbeAeVGVU2wm45~CsNT7Z9L5tq0Z5dXBxPUlN1iGGe9MlXLz9LT4u8nPj8eJqSPS6RNVhSUfahBgFQB3vdU5ZTypcQWkhiUI02EIddHdojbJ2sWSNeTfSVseSriG1ph0kkS34CU6GSxNSR8o6GjkgOw5-KT56LS4scomb3ldphoBcH9Cv1u5lDNFCYfaz-jp8ClGoMgWryYQEsSsAL3Ve1upoSsLNRAWhc1A~t0RdDaZGZU99LuAgHRx4qF6OThj8MhwoH~~1bzEt~rRUW08D-svMWTesoQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "pagetype": "article", "links": ["#skipNav", "javascript:;", "/", "javascript:;", "javascript:;", "/pages/who-we-serve", "/pages/researchers", "/pages/authors", "/pages/reviewers", "/pages/healthcare-professionals", "/pages/patients", "/pages/librarians", "/pages/health-sciences-industry", "/pages/society", "/pages/agents-distributors-booksellers", "javascript:;", "/pages/what-we-offer", "/pages/journals", "/pages/online-collections", "/collections/subject-area", "/pages/books", "https://courses.karger.com/", "/pages/podcasts", "javascript:;", "/pages/what-we-solve", "/pages/accessing-knowledge", "/pages/presenting-knowledge", "/pages/applying-knowledge", "/pages/about-us", "javascript:;", "/pages/publish-with-us", "/pages/publish-your-paper", "/pages/calls-for-papers", "/pages/publication-services", "/pages/partner-publications", "javascript:;", "/pages/resources-for-you", "/pages/newsroom", "/pages/exhibitions-and-webinars", "/pages/fast-facts-titles", "https://experience.karger.com/", "https://thewaitingroom.karger.com/", "https://www.embarrassingproblems.com/", "https://nephrologyviewpoints.karger.com/", "javascript:;", "javascript:;", "/advanced-search", "https://karger.com/store/cart", "javascript:;", "https://karger.com/store/cart", "/my-account/register?siteId=1000135&returnUrl=%2fkkp%2farticle%2f11%2f2%2f73%2f833144%2fLong-COVID-Impfung-und-fruhe-antivirale-Therapie", "javascript:;", "//karger.com/kkp", "javascript:;", "javascript:;", "/kkp/search-results?fl_SiteID=1000003&page=1&f_ContentType=Journal+Articles", "/kkp/issue-covers", "/pages/rights-and-permissions", "/kkp/pages/fokus", "/kkp/pages/blickdiagnose", "javascript:;", "/kkp/pages/details", "/kkp/pages/contact", "/kkp/pages/editorial-board", "/kkp/pages/guidelines", "/pages/rights-and-permissions", "/pages/advertising", "#", "/kkp/issue/11/2", "/kkp/issue/11/2", "#13697569", "#13697575", "#13697583", "https://karger.com/kkp/collection/191062/Focus-Article", "https://karger.com/kkp/collection/41/Pneumology", "javascript:;", null, "mailto:kruegerst@kaiserswerther-diakonie.de", "/kkp/search-results?f_AllAuthors=Stefan+Kr%c3%bcger", "http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Kr\u00fcger S", "http://scholar.google.com/scholar?q=author:\"Kr\u00fcger S\"", "mailto:kruegerst@kaiserswerther-diakonie.de", "https://doi.org/10.1159/000530014", "javascript:;", "/kkp/article-split/11/2/73/833144/Long-COVID-Impfung-und-fruhe-antivirale-Therapie", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "/kkp/article-pdf/11/2/73/3959631/000530014.pdf", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "javascript:;", "https://s100.copyright.com/AppDispatchServlet?publisherName=KARGER&publication=2296-0317&title=Long-COVID%3A%20Impfung%20und%20fr%C3%BChe%20antivirale%20Therapie%20senken%20das%20Risiko&publicationDate=2023-04-20&volumeNum=11&issueNum=2&author=Kr%C3%BCger%2C%20Stefan&startPage=73&endPage=74&contentId=10.1159%2F000530014&oa=&copyright=Silverchair%20Publisher&orderBeanReset=True", "javascript:;", "javascript:;", "https://doi.org/10.1159/000530014", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=0", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=0", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=0", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=0", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=0", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=0", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=1", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=3", "/Citation/Download?resourceId=833144&resourceType=3&citationFormat=2", "javascript:;", "javascript:;", "/advanced-search", "/kkp/search-results?qb={\"Keywords1\":\"long+COVID\"}", "/kkp/search-results?qb={\"Keywords1\":\"post-COVID+syndrome\"}", "/kkp/search-results?qb={\"Keywords1\":\"COVID-19\"}", "/kkp/search-results?qb={\"Keywords1\":\"SARS-CoV-2\"}", "/kkp/search-results?qb={\"Keywords1\":\"monoclonal+antibodies\"}", "/kkp/search-results?qb={\"Keywords1\":\"antivirals\"}", null, null, "javascript:;", null, "javascript:;", "javascript:;", "javascript:;", "http://scholar.google.com/scholar?q=link:https%3A%2F%2Fkarger.com%2Fkkp%2Farticle%2F11%2F2%2F73%2F833144", "javascript:;", "javascript:;", "javascript:;", "/kkp/article/doi/10.1159/000534546/867609/Nicht-kleinzellige-Lungentumoren-Fruhzeitige", "/kkp/article/doi/10.1159/000534462/867456/Pleuraergusse-Serum-Erguss-Albumin-Gradient", "/kkp/article/doi/10.1159/000533780/865133/Aktuelle-Ansatze-zur-neoadjuvanten-Immuntherapie", "/kkp/article/doi/10.1159/000533781/865134/Nivolumab-induzierte-Pneumonie-bei-nicht", "/kkp/article/doi/10.1159/000534325/864755/ILD-Wann-brauchen-wir-die-chirurgische", "/aha/article/145/3/275/827310/Challenges-and-Management-of-Long-COVID-in", "/res/article/102/2/120/842100/Pulmonary-Recovery-12-Months-after-Non-Severe-and", "/kkp/article/11/2/110/833142/Beeintrachtigung-der-inspiratorischen", "/drm/article/237/1/1/115014/Skin-Manifestations-Associated-with-COVID-19", "/pages/contact-and-support", "/pages/information-and-downloads", "/pages/rights-and-permissions", "/pages/terms-and-conditions", "/pages/catalogue-and-pricing", "/pages/company", "/pages/people-and-organisation", "/pages/newsroom", "/pages/careers", "/pages/newsletters", "/pages/exhibitions-and-webinars", "/pages/regional-offices", "/pages/community-voice", "/pages/researchers", "/pages/authors", "/pages/reviewers", "/pages/healthcare-professionals", "/pages/patients", "/pages/librarians", "/pages/health-sciences-industry", "/pages/society", "/pages/agents-distributors-booksellers", "/pages/contact-and-support", "#", "https://www.facebook.com/KargerPublishers/", "https://www.linkedin.com/company/karger-publishers", "https://x.com/KargerPublisher", "https://www.youtube.com/channel/UCnpxr2XR2_ikKqYrdbajSAw", "/ImageLibrary/umbrella/WeChat_QRcode.jpg", "https://experience.karger.com", "/pages/privacy-policy", "/pages/terms-of-use", "/pages/imprint", "javascript:void(0);", "javascript:;", "javascript:;", "/sign-in?returnUrl=%2fkkp%2farticle%2f11%2f2%2f73%2f833144%2fLong-COVID-Impfung-und-fruhe-antivirale-Therapie", "/my-account/register?siteId=1000135&returnUrl=%2fkkp%2farticle%2f11%2f2%2f73%2f833144%2fLong-COVID-Impfung-und-fruhe-antivirale-Therapie", "javascript:;", "javascript:;"]}